论文部分内容阅读
麦迪霉素是1974年从我国土壤中分离的链霉菌(Streptomyces Sp.)1748所产生的抗菌素。根据理化性质的研究证实与日本的麦地加霉素(Mydecamycin)相同。本文通过体内外抗菌活性的研究证明麦迪霉素对金黄色葡萄球菌、链球菌和肺炎双球菌等革兰氏阳性菌具有较强的抗菌作用,最低抑菌浓度为0.19～3.12μg/ml。诱导耐药实验证实麦迪霉素属于非诱导型抗菌素。在实验治疗的比较试验中证明麦迪霉素对小白鼠感染金黄色葡萄球菌、溶血性链球菌和肺炎双球菌的治疗效果与日本的麦地加霉素相同或优于后者。
Midecamycin is an antibiotic produced by Streptomyces Sp. 1748, isolated from the soil of our country in 1974. According to the physical and chemical properties of the study confirmed that Japan and the same medemycin (Mydecamycin). In this paper, antibacterial activity in vitro and in vivo studies have shown that midecamycin Staphylococcus aureus, Streptococcus pneumoniae and other Gram-positive bacteria have strong antibacterial activity, the minimum inhibitory concentration of 0.19 ~ 3.12μg / ml. Induction of drug resistance experiments confirmed that midecamycin is a non-inducible antibiotic. In the comparative experiment of experimental treatment, the effect of midecamycin on mice infected with Staphylococcus aureus, hemolytic streptococcus and pneumococcus was proved to be the same as or better than that of Japan.